Cargando…

Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events

BACKGROUND: IgG4 anbibodies are deficient in stability and may contribute to tumor-associated escape from immune surveillance. We developed an IgG1 backbone anti-programmed cell death protein-1 (PD-1) antibody, penpulimab, which is designed to remove crystallizable fragment (Fc) gamma receptor (FcγR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Zhaoliang, Pang, Xinghua, Zhong, Tingting, Qu, Tailong, Chen, Na, Ma, Shun, He, Xinrong, Xia, Dennis, Wang, Max, Xia, Michelle, Li, Baiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272907/ https://www.ncbi.nlm.nih.gov/pubmed/35833116 http://dx.doi.org/10.3389/fimmu.2022.924542

Ejemplares similares

Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity
por: Qu, Tailong, et al.
Publicado: (2022)

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
por: Pang, Xinghua, et al.
Publicado: (2023)

Specificity of fc receptors for IgG2a, IgG1/IgG2b, and IgE on rat macrophages
Publicado: (1981)

IgG4 antibodies from patients with asymptomatic bancroftian filariasis inhibit the binding of IgG1 and IgG2 to C1q in a Fc-Fc-dependent mechanism
por: Prodjinotho, Ulrich F., et al.
Publicado: (2019)

Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality
por: Tam, Susan H., et al.
Publicado: (2017)

Engineered IgG1‐Fc – one fragment to bind them all
por: Lobner, Elisabeth, et al.
Publicado: (2016)

Impact of IgG1 N-glycosylation on their interaction with Fc gamma receptors
por: Cambay, Florian, et al.
Publicado: (2020)

Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies
por: Golay, Josée, et al.
Publicado: (2022)

B-lymphocytes activation by the Fc region of IgG
Publicado: (1977)

Fc-Mediated Functions of Porcine IgG Subclasses
por: Paudyal, Basudev, et al.
Publicado: (2022)

Human IgG/FcγR Interactions Are Modulated by Streptococcal IgG Glycan Hydrolysis
por: Allhorn, Maria, et al.
Publicado: (2008)

Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways
por: Lilienthal, Gina-Maria, et al.
Publicado: (2018)

The role of Fc–FcγR interactions in IgG-mediated microbial neutralization
por: Bournazos, Stylianos, et al.
Publicado: (2015)

Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human FcγRI
por: Bonetto, Stephane, et al.
Publicado: (2009)

Mouse IgG2c Fc loop residues promote greater receptor-binding affinity than mouse IgG2b or human IgG1
por: Falconer, Daniel J., et al.
Publicado: (2018)

Stabilisation of the Fc Fragment of Human IgG1 by Engineered Intradomain Disulfide Bonds
por: Wozniak-Knopp, Gordana, et al.
Publicado: (2012)

Interactions of IgG1 CH2 and CH3 Domains with FcRn
por: Ying, Tianlei, et al.
Publicado: (2014)

IgG1 Fc N-glycan galactosylation as a biomarker for immune activation
por: de Jong, Sanne E., et al.
Publicado: (2016)

Effect of Fc core fucosylation and light chain isotype on IgG1 flexibility
por: Saporiti, Simona, et al.
Publicado: (2023)

Pharmacokinetic Models for FcRn-Mediated IgG Disposition
por: Xiao, Jim J.
Publicado: (2012)

IgG-Fc glycoengineering in non-mammalian expression hosts
por: Loos, Andreas, et al.
Publicado: (2012)

Crystal structure of deglycosylated human IgG4-Fc
por: Davies, Anna M., et al.
Publicado: (2014)

Generation and Characterization of an IgG4 Monomeric Fc Platform
por: Shan, Lu, et al.
Publicado: (2016)

IgG Fc engineering to modulate antibody effector functions
por: Wang, Xinhua, et al.
Publicado: (2017)

IgG and Fcγ Receptors in Intestinal Immunity and Inflammation
por: Castro-Dopico, Tomas, et al.
Publicado: (2019)

The role of IgG Fc receptors in antibody-dependent enhancement
por: Bournazos, Stylianos, et al.
Publicado: (2020)

Impact of Fc N-glycan sialylation on IgG structure
por: Zhang, Zhongqi, et al.
Publicado: (2019)

The therapeutic potential of sialylated Fc domains of human IgG
por: Pleass, Richard J.
Publicado: (2021)

Synthetic nanobodies as tools to distinguish IgG Fc glycoforms
por: Kao, Kevin S., et al.
Publicado: (2022)

IgG Suppresses Antibody Responses in Mice Lacking C1q, C3, Complement Receptors 1 and 2, or IgG Fc-Receptors
por: Bergström, Joakim J. E., et al.
Publicado: (2015)

Correction: Mouse IgG2c Fc loop residues promote greater receptor-binding affinity than mouse IgG2b or human IgG1
Publicado: (2018)

Fc-Linked IgG N-Glycosylation in FcγR Knock-Out Mice
por: Zaytseva, Olga O., et al.
Publicado: (2020)

The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement
por: Brinkhaus, Maximilian, et al.
Publicado: (2022)

Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s
por: Tolbert, William D., et al.
Publicado: (2022)

Penpulimab-induced complete atrioventricular block in a patient with metastatic renal cancer
por: Shen, Lishui, et al.
Publicado: (2023)

Fc-Glycosylation in Human IgG1 and IgG3 Is Similar for Both Total and Anti-Red-Blood Cell Anti-K Antibodies
por: Sonneveld, Myrthe E., et al.
Publicado: (2018)

C-Reactive Protein Enhances IgG-Mediated Cellular Destruction Through IgG-Fc Receptors in vitro
por: Temming, A. Robin, et al.
Publicado: (2021)

In Vitro Glycoengineering of IgG1 and Its Effect on Fc Receptor Binding and ADCC Activity
por: Thomann, Marco, et al.
Publicado: (2015)

The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation
por: Fickentscher, Christoph, et al.
Publicado: (2015)

Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid
por: Wuhrer, Manfred, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ck4j40dflio8ulj3ufguge9ad7